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Abstract 
Background: Surgery, radiation therapy, drug therapy or a combination of these methods can be used 
for the treatment of malignancies. Drug therapy in cancer patients includes of chemotherapy, 
Biotherapy and use of monoclonal antibodies against antigens of malignant cells. One of the 
compounds that was used as drugs in chemotherapy against malignant cells, are heavy metal 
complexes. The present study aimed to assess the effects new anticancer palladium complexes have 
been performed on esophageal cancer cells. 
Methods: New palladium complexes, namely [(phen) Pd (µ-al-bis-dtc) Pd (phen)] (NO3)2 (where 
alkylenebisdithiocarbamate, al-bis-dtc= propylenebisdithiocarbamate (pn-bis-dtc, 1); 
butylenebisdithiocarbamate (bu-bis-dtc, 2); octylenebis- dithiocarbamate (oc-bis-dtc, 3) and 
phen=1,10-phenanthroline) was synthesized in the laboratory of Chemistry, University of Sistan and 
Baluchestan. In order to investigate the anticancer effects of three new complexes compared to 
cisplatin on esophageal cancer cell line (KYSE-30), cytotoxicity was examined through MTT and 
clonogenic assays. Ethidium bromide/acridine orange (EB/AO) staining was used for apoptotic and 
necrotic cells detection. 
Findings: The results of MTT and clonogenic assays showed that the IC50 value obtained from cells 
treated with complexes 1, 2 and 3 were much lower than cisplatin and also Ethidium bromide/acridine 
orange staining demonstrated that three new Complexes apply its cytotoxic effect via apoptotic 
pathway. Comparing the number of colonies formed after treatment with various concentrations of 
palladium complexes, showed significant differences compared with control. (P < 0.001). 
Conclusion: Findings of this study showed that anti-tumor effect of three new Complexes on KYSE-
30 cell line were higher than that of cisplatin. And even the use of low concentrations of palladium 
complexes can reduce the number of colonies and induces cell death by apoptosis and if it can do 
further researches later be used as an alternative drug in the treatment of esophageal cancer. 
Keywords: KEYSE-30, New palladium complexes, Colony assay, Apoptosis, Necrosis 
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